

## Special Issue

# Precision Medicine for Adolescent and Young Adult (AYA) Oncology

### Message from the Guest Editor

Adolescents and young adults (AYA, ages 15–39years) affected by cancer have unique treatment, survivorship, and palliation concerns. Precision medicine for adolescent and young adult (AYA) oncology is a rapidly growing field. With a focus on the unique challenges that this age group presents, the issue highlights the importance of precision medicine in improving outcomes and reducing side effects. This Special Issue presents cutting-edge research and clinical advances in precision medicine for AYA oncology. Articles in this issue cover a range of topics, including genomic profiling, targeted therapies, and supportive care for AYA patients. This Special Issue also discusses the use of immunotherapy in AYA oncology, including the challenges and opportunities of using such therapies on this patient population. Original papers are especially encouraged; however, high-level systematic reviews or meta-analyses will also be considered for publication.

### Guest Editor

Dr. Amirtha Srikanthan

1. Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada
2. Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada
3. The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada

### Deadline for manuscript submissions

25 December 2024



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/172841](https://mdpi.com/si/172841)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).